SUNNYVALE, Calif., Jan. 19, 2021 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that data from a
prospective, phase II trial of 338 women with low-risk breast
cancer showed 98.8 percent had local disease control seven years
after receiving once-daily accelerated partial breast irradiation
(APBI) delivered with the TomoTherapy® System. The
study, published online in the International Journal of
Radiation Oncology*Biology*Physics, also reported that the
once-daily schedule was associated with a very low incidence of
acute and late toxicities.
The TomoTherapy platform, including the next-generation
Radixact® System, is the first in the world capable of
helical radiation delivery. Image-guided, intensity-modulated
radiation therapy (IG-IMRT) is continuously delivering from a full
360 degrees around the patient as the treatment table also moves at
a deliberate pace, providing greater control of the radiation dose
so it conforms precisely to the tumor and helps minimize dose to
healthy tissue. This precision enables medical care teams to
deliver hypofractionated treatment regimens - a higher dose per
fraction in fewer fractions than conventional schedules - such as
APBI, with increased confidence.
"Over the last 10 years, breast-conserving surgery and APBI have
been widely used in clinical practice for the treatment of low-risk
breast cancer. Our large phase 2 trial demonstrated that IG-IMRT
delivered using the TomoTherapy System offers improvements over
existing techniques and can provide better APBI outcomes in
carefully selected patient populations. The system enabled our team
to increase the conformality and homogeneity of the dose to the
tumor bed and reduce the dose to surrounding healthy tissue, making
APBI an effective and convenient option for our patients," said
Prof. Ugo de Paula, Department of
Radiation Oncology, San Giovanni-Addolorata Hospital, Rome, Italy.
Enhanced precision enables excellent long-term results: study
highlights
Once-daily breast APBI delivered with the TomoTherapy System
demonstrated the following:
- Ipsilateral breast tumor recurrence (IBTR) free control was
99.4% at a median follow-up of 76 months. This is important because
patients with IBTR may be at high risk for subsequent distant
metastasis;
- Locoregional control (no recurrence in ipsilateral breast as
well as in regional nodes) was 98.8% at a median follow-up of 76
months;
- Progression-free survival was 98.4% and 92% at 5 and 10
years;
- Treatments were very well tolerated with minimal acute or late
side effects. Importantly, there were no cases observed of late
toxicity such as pneumonitis or rib fractures;
- More than 95 percent of patients and their physicians rated
cosmesis -- preservation of the normal appearance of the breast --
as good/excellent at two years, the relevant timepoint for
evaluation of cosmesis.
"This study builds on existing clinical evidence demonstrating
the benefits of the TomoTherapy System in the treatment of breast
cancer. Integrated image guidance and helical radiation delivery
enables exceptional homogeneity in radiation dose delivery and
superior treatments for patients. Dr. de Paula and his colleagues
found that even those patients deemed cautionary or unsuitable for
APBI by American Society of Radiation Oncology (ASTRO) criteria
experienced a low rate of IBTR," said Fabienne
Hirigoyenberry-Lanson, Ph.D., vice president global medical and
scientific affairs, at Accuray.
About the Phase II Trial
In this trial, 338 women with low-risk breast cancer received a
treatment dose of 3.85 Gray (Gy)
delivered by the TomoTherapy® System in 10 consecutive
daily fractions, five days per week. Patients who had previously
undergone breast-conserving surgery were enrolled in the study. The
primary endpoints of this trial were breast tumor recurrence, and
acute and late toxicity. Secondary outcomes were progression-free
survival (PFS) and rates of adverse cosmesis.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions to deliver radiation treatments
for even the most complex cases—while making commonly treatable
cases even easier—to meet the full spectrum of patient needs. We
are dedicated to continuous innovation in radiation therapy for
oncology, neuro-radiosurgery, and beyond, as we partner with
clinicians and administrators, empowering them to help patients get
back to their lives, faster. Accuray is headquartered in
Sunnyvale, California, with
facilities worldwide. To learn more, visit www.accuray.com or
follow us on Facebook, LinkedIn, Twitter, and YouTube.
Accuray
Beth Kaplan
Tel: +1 (408) 789-4426
E-mail: bkaplan@accuray.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/seven-year-data-shows-accuray-tomotherapy-system-provides-excellent-long-term-control-of-low-risk-breast-cancer-301210300.html
SOURCE Accuray Incorporated